Corcept Therapeutics Incorporated Stock 12‑Month Price Target Raised to $142.6, Implies 74% Upside

What happened

Analysts’ average 12-month price target for Corcept Therapeutics Incorporated rose from $141 to $142.6, according to estimates from five analysts. Based on the Nov. 3 closing price, the updated target implies approximately 74% potential upside. The consensus rating remained Buy among seven covering analysts.

Confirmed

Global impact / market context

A higher target can influence investor expectations by presenting a more optimistic estimate of what the shares could be worth, but it is not a promised return. The reported Buy consensus was unchanged, and analysts’ estimates vary widely.

Analyst inference

The target increase is a change in analysts’ forecasts, not a reported change in Corcept’s sales, costs, or cash available. If investors act on the higher estimate, their buying or selling could affect demand for the shares, though no market reaction is reported.

Analyst inference

What to watch

1. Future analyst target updates can indicate whether the average forecast continues rising or falls; five analysts’ estimates currently contribute to the reported average. Analyst inference
2. Watch for changes in the seven-analyst rating mix: five Buys, one Hold, and one Sell. A changed mix could alter the reported consensus rating. Analyst inference
3. Compare any later estimate with the share price used to calculate its implied upside, because the reported 74% figure relies on the Nov. 3 closing price. Analyst inference

Evidence

• Original source link unavailable